Literature DB >> 1384375

Metastasizing mixed tumor of salivary glands. A clinicopathologic and flow cytometric analysis.

B M Wenig1, C L Hitchcock, G L Ellis, D R Gnepp.   

Abstract

Among salivary gland neoplasms are a group of rare tumors that are histologically identical to benign mixed tumors that inexplicably metastasize; they have been called metastasizing mixed tumor (MZMT) of salivary glands. We report the clinicopathologic features and flow cytometric findings for 11 cases of MZMT. At the time of discovery of metastatic disease, the patients, six women and five men, ranged in age from 20 to 83 years. Primary sites of involvement included the parotid gland (eight cases), submandibular gland (two cases), and the nasal septum (one case). With one exception, all the patients had at least a single recurrences of their primary mixed tumor, but two or more recurrences were the norm before development of metastatic foci. The metastases were discovered from six to 52 years following the occurrence of the primary tumor. Metastatic deposits were identified in bone, lung, regional lymph nodes, skin, kidney, retroperitoneum, oral cavity, pharynx, calvarium, and central nervous system. The metastases either occurred simultaneously with an episode of recurrent mixed tumor (n = 5) or from 5 to 29 years after a recurrence (n = 6). The treatment of the primary, recurrent, and metastatic neoplasms was surgical excision. Follow-up, ranging from 8 months to 16 years following the diagnosis of MZMT, revealed seven patients to be alive without disease (64%) and two dead of causes unrelated to metastatic disease (18%). Two patients (18%) died as a direct result of metastatic tumor at 3 and 2 years after metastasis of their mixed tumors. Flow cytometric analysis revealed a diploid DNA cell population in the primary and/or metastatic tumors in nine cases. Aneuploid DNA cell content was identified in two of the cases. DNA ploidy levels and cell proliferation rates were compared with those of conventional benign mixed tumors and also with malignant mixed tumors. Retrospective analysis of histologic parameters (mitotic rate, cellular pleomorphism, infiltrative growth, vascular or lymphatic invasion) and flow cytometric analysis failed to identify criteria to predict the development of metastasis in these neoplasms.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1384375     DOI: 10.1097/00000478-199209000-00003

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  7 in total

1.  Gray scale and doppler ultrasonography features of the carcinoma ex pleomorphic adenoma.

Authors:  Ding Angang; Li Jia; Gong Xia; Xiong Ping; Li Jiang
Journal:  Dentomaxillofac Radiol       Date:  2018-02-13       Impact factor: 2.419

2.  Pleomorphic adenoma of nasal septum: a rare case.

Authors:  Shama Shetty; Dipak Ranjan Nayak; Padmapriya Jaiprakash
Journal:  BMJ Case Rep       Date:  2018-03-28

Review 3.  Carcinoma ex pleomorphic adenoma, with particular emphasis on early lesions.

Authors:  Silvana Di Palma
Journal:  Head Neck Pathol       Date:  2013-07-03

Review 4.  Metastasizing Pleomorphic Adenoma Case Report and Review of the Literature.

Authors:  Rana Alshagroud; Amandip Kamoh; Saurin R Popat; Margaret Brandwein-Weber; Alfredo Aguirre
Journal:  Head Neck Pathol       Date:  2017-05-25

5.  Aneuploidy in salivary gland adenomas.

Authors:  T Atula; R Grénman; P Laippala; P J Klemi
Journal:  Eur Arch Otorhinolaryngol       Date:  1995       Impact factor: 2.503

6.  Metastasizing pleomorphic adenoma presenting as an asymptomatic kidney tumor twenty-nine years after parotidectomy - urological viewpoint and overview of the literature to date.

Authors:  Jan Ebbing; Carolin Blind; Harald Stein; Kurt Miller; Christoph Loddenkemper
Journal:  Rare Tumors       Date:  2009-12-28

7.  Metastasizing pleomorphic adenoma in the multiple organs: A case report on FDG-PET/CT imaging.

Authors:  Masamichi Koyama; Takashi Terauchi; Mitsuru Koizumi; Hiroko Tanaka; Yukiko Sato
Journal:  Medicine (Baltimore)       Date:  2018-06       Impact factor: 1.889

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.